We are back in Barcelona for Reuters Pharma 2024, bringing you all the highlights and talking points from Day One of the conference. Stay tuned for updates throughout the day.
Our ability to turn great products into great medicines has never been more reliant on how we engage with our patients, yet we’re still falling short of expectations and failing to build su
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh